Table 2

 Clinical, morphological, biochemical, and haematological characteristics in normal controls and patients with chronic pancreatitis or Sjögren’s syndrome

ControlsICPAlcoholic CPSjögren’s syndrome
Results are expressed as percentage (number of positive cases/total number of cases).
CP, chronic pancreatitis; ICP, idiopathic chronic pancreatitis; ANA, antinuclear antibodies; Ab, antibodies; Eosinophilia, >350×109 eosinophils/l.
*p<0.05, **p<0.01 versus controls; †p<0.05, ††p<0.01 versus ICP.
Attacks of pancreatitis0 (0/54)33.3 (18/54)**81.4 (70/86)**††0 (0/33)††
Abdominal pain0 (0/54)60.4 (32/54)**91.9 (79/86)**††9.1 (3/33)*††
Cholestasis/jaundice0 (0/54)22.2 (12/54)**27.9 (24/86)**0 (0/33)††
Associated autoimmune disorders0 (0/54)35.2 (19/54)**22.1 (19/86)**69.7 (23/33)**††
Pancreatic mass0 (0/54)24.1 (13/54)**2.4 (2/86)**†0 (0/33)††
Calcifications0 (0/54)44.4 (24/54)**82.6 (71/86)**††0 (0/33)††
Pseudocysts0 (0/54)16.7 (9/54)**49.4 (42/85)**††0 (0/33)†
Eosinophilia5.6 (3/54)13.0 (7/54)12.8 (11/86)0 (0/33)†
ANA7.4 (4/54)13 (7/54)10.5 (9/86)51.5 (17/33)**††
Antimitochondrial Ab0 (0/54)3.7 (2/54)1.2 (1/86)6.1 (2/33)
Antismooth muscle Ab1.9 (1/54)5.6 (3/54)7.1 (6/85)3 (1/33)
SS-B0 (0/54)1.9 (1/54)1.2 (1/86)39.4 (13/33)**††